20D Stock Overview
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Cidara Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.62 |
52 Week High | US$2.02 |
52 Week Low | US$0.57 |
Beta | 0.94 |
1 Month Change | 0% |
3 Month Change | -3.71% |
1 Year Change | -63.43% |
3 Year Change | -67.16% |
5 Year Change | -72.31% |
Change since IPO | -95.50% |
Recent News & Updates
Recent updates
Shareholder Returns
20D | DE Biotechs | DE Market | |
---|---|---|---|
7D | 3.8% | 0.06% | 0.07% |
1Y | -63.4% | 28.6% | 4.9% |
Return vs Industry: 20D underperformed the German Biotechs industry which returned 28.1% over the past year.
Return vs Market: 20D underperformed the German Market which returned 5% over the past year.
Price Volatility
20D volatility | |
---|---|
20D Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 20D has not had significant price volatility in the past 3 months.
Volatility Over Time: 20D's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 73 | Jeff Stein | https://www.cidara.com |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company’s lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.
Cidara Therapeutics, Inc. Fundamentals Summary
20D fundamental statistics | |
---|---|
Market cap | €59.26m |
Earnings (TTM) | -€28.11m |
Revenue (TTM) | €51.77m |
1.2x
P/S Ratio-2.3x
P/E RatioIs 20D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
20D income statement (TTM) | |
---|---|
Revenue | US$56.54m |
Cost of Revenue | US$73.63m |
Gross Profit | -US$17.08m |
Other Expenses | US$13.61m |
Earnings | -US$30.70m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.34 |
Gross Margin | -30.22% |
Net Profit Margin | -54.29% |
Debt/Equity Ratio | 0% |
How did 20D perform over the long term?
See historical performance and comparison